Forte Biosciences, Inc.
NASDAQ:FBRXBiotechnology
+$0.30 today
- Market cap
- $1.58B
- Beta
- 2.87
- P/E (TTM)
- -42.1
- EPS (TTM)
- -$0.43
Volume 0.00M
Average 0.30M
FBRX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Forte Biosciences, Inc.NASDAQ: FBRX
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities falls 29.8% from a year ago
Other current liabilities stood at $878K at the end of Q1 FY2026, down 29.8% from a year earlier and down 61.0% from the prior quarter. Over 3 fiscal years it compounded at +36.2% a year.
Context
- Other current liabilities amounted to 1.3% of total assets at the end of Q1 FY2026, down 1.3 pp from a year earlier.
- Other current liabilities increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps falling in the next quarterly balance sheet after a -29.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 2.25M USD
- Year-over-year change
- +45.1%
- 4-year CAGR
- +34.8%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.25M | +45.1% |
| FY2024 | 2024-12-31 | 1.55M | +63.8% |
| FY2023 | 2023-12-31 | 947K | +6.4% |
| FY2022 | 2022-12-31 | 890K | +30.7% |
| FY2021 | 2021-12-31 | 681K | — |
Other Current Liabilities vs competitors
How FBRX compares with its peers on the latest reported figures
- Peers report in different currencies, so other current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -29.8% is the 7th highest of 9, against a peer median of +79.6%.
- Other current liabilities amounts to 1.3% of total assets for FBRX, versus a peer median of 3.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $15.27M USD | +1428.1% | +326.4% | 10.6% | |
| Mar 2026 | $8.45M USD | -29.8% | -40.5% | 3.0% | |
ELTXElicio Therapeutics, Inc. | Mar 2026 | $5.92M USD | +329.2% | +78.6% | 26.1% |
| Mar 2026 | $4.53M USD | +248.6% | +9.5% | 9.2% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $3.52M USD | +184.4% | +20.0% | 39.5% |
| Mar 2026 | $2.98M USD | -51.3% | -13.4% | 0.8% | |
| Mar 2026 | $1.43M USD | -25.2% | +24.1% | 0.9% | |
| Mar 2026 | $878K USD | -29.8% | +36.2% | 1.3% | |
| Mar 2026 | $0 USD | -100.0% | +24.1% | 0.0% | |
| Mar 2026 | -CHF 20.53K CHF | — | — | 0.0% | |
| Peer median (excluding FBRX) | — | +79.6% | +22.0% | 3.0% | |
Competitors are the stored peer set for FBRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Forte Biosciences, Inc.
NASDAQ:FBRX
Intrinsic Alpha fair value
Locked
Current Price
$76.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.